Cyclobenzaprine Hcl Er has 9 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 5 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Mao Inhibitors, Bupropion, Meperidine. Patients taking Cyclobenzaprine Hcl Er should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 9
- Contraindicated
- 1
- Major
- 5
- Moderate
- 3
Contraindicated (1)
- Cyclobenzaprine Hcl Er + Mao Inhibitors— Life-threatening interaction with MAO inhibitors; serotonin syndrome reported during combined use.
Major (5)
- Cyclobenzaprine Hcl Er + Bupropion— Postmarketing cases of serotonin syndrome reported during combined use with bupropion.
- Cyclobenzaprine Hcl Er + Meperidine— Postmarketing cases of serotonin syndrome reported during combined use with meperidine.
- Cyclobenzaprine Hcl Er + Tcas— Postmarketing cases of serotonin syndrome reported during combined use with tricyclic antidepressants.
- Cyclobenzaprine Hcl Er + Tramadol— May enhance seizure risk and serotonin syndrome has been reported during combined use.
- Cyclobenzaprine Hcl Er + Verapamil— Postmarketing cases of serotonin syndrome reported during combined use with verapamil.
Moderate (3)
- Cyclobenzaprine Hcl Er + Alcohol— Cyclobenzaprine may enhance the effects of alcohol.
- Cyclobenzaprine Hcl Er + Barbiturates— Cyclobenzaprine may enhance the effects of barbiturates.
- Cyclobenzaprine Hcl Er + Guanethidine— Cyclobenzaprine may block the antihypertensive action of guanethidine.